​​​​​​​PsA Treatment Options Expand

• by Kathryn Wighton

• March 9, 2026

FDA Approves New Oral Option for Plaque Psoriasis

Phase 3 data showed high skin clearance rates and adverse event rates similar to placebo through week 16 with once-daily icotrokinra.

• by Kathryn Wighton

• March 18, 2026

• 2 min

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

• by Kathryn Wighton

• February 18, 2026

• 3 min

Associations of Lifestyle-Related Factors and Psoriatic Arthritis Disease Activity: The Dutch South West Psoriatic Arthritis Study

• by Batoul Hojeij, Ilja Tchetverikov, Marc R. Kok, Marijn Vis, Yvonne Goekoop-Ruiterman, Jessica Bijsterbosch, Paul Baudoin, Reinhard Bos, Jos H. van der Kaap, Petra Kok, Lindy-Anne Korswagen, Jolanda J. Luime

• May 16, 2026